The strategic partnership marks the first-ever MoU for medicinal cannabis research between any Australian and Japanese organisation or government.
The MoU swiftly follows the Japanese Government’s recent change in stance towards the use of cannabis with the Lower House passing the bill to legalise the use of medical products made from cannabis in mid-November.
“We are honoured to be the first Australian business to have a MoU for medicinal cannabis research with a Japanese organisation” says Cannatrek CEO Tommy Huppert.
“Cannatrek has the manufacturing capability to supply the highest quality of medicinal cannabis products for domestic and international markets via our Shepparton facility. The facility recently received Good Manufacturing Practice (GMP) accreditation which further enhances export opportunities.”
Under the MoU, the framework for cooperation encompasses several key areas including agronomic research, training resources for clinicians, pharmaceutical supply chain, e-healthcare, navigating regulation and compliance and connecting experts in the field.
Within agronomic research, it will see the establishment of a medicinal cannabis breeding lab at Mie University focused on stabilising specific cultivars to pioneer a medicinal cannabis genetic library.
Cannatrek will also lend its expertise in supply chain management grounded by their seed to patient model by mapping out the optimal journey of medicinal cannabis products in Japan through healthcare providers and after-care services to patients in need.